(All fields required)
Please enter a valid email.
Please enter your name.
Showing 11 - 16 of 16 records.
This phase II trial studies how well chemotherapy and radiation therapy work in treating younger patients with newly diagnosed central nervous system germ cell tumors....More
This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with relapsed or refractory solid tumors. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth....More
The purpose of this study is to find a recommended dose level of LY2940680 that can be safely given to children with medulloblastoma or rhabdomyosarcoma that has returned or doesn't respond to initial treatment. The study will also explore the changes in a cancer marker levels. Finally, the study w...More
This phase I trial
studies the side effects and best dose of azurin-derived cell-penetrating
peptide p28 (p28) in treating patients with recurrent or progressive central
nervous system tumors. Drugs used in chemotherapy, such as azurin-derived
cell-penetrating peptide p28, work in different way...More
This phase I/II trial studies the side effects
and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in
treating younger patients with solid tumors that have come back or that have
not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan
hydrochloride may stop the...More
This phase II trial studies how well
peginterferon alfa-2b works in treating younger patients with craniopharyngioma
that is recurrent or cannot be removed by surgery. Peginterferon alfa-2b may
interfere with the growth of tumor cells and slow the growth of
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2014 Cincinnati Children's Hospital Medical Center